Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Diabetic Peripheral Neuropathic Pain
Latest Information Update: 16 Jan 2026
At a glance
- Drugs LY 4065967 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Acronyms NP07
- Sponsors Eli Lilly and Company
Most Recent Events
- 12 Jan 2026 Status changed from not yet recruiting to recruiting.
- 23 Dec 2025 New trial record